Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的枸橼酸莫沙必利片《药品注册证书》，现 将相关情况公告如下： 证券代码：603538 证券简称：美诺华 公告编号：2025-097 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 关于全资子公司获得枸橼酸莫沙必利片 药品注册证书的公告 药品适应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎） 引起的消化道症状，包括烧心、嗳气、恶心、呕吐、早饱、上腹胀、上腹痛等。 国产药品注册的申请并获得受理。截至本公告日，公司已投入研发费用为人民币 由于医药产品的行业特点，该药品未来销售情况可能受到政策变化、市场需 求、同类型药品市场竞争等多种不确定因素影响，具有较大不确定性，敬请广大 投资者注意投资风险。 特此公告。 一、药品相关信息 宁波美诺华药业股份有限公司 本品符合药品注册的有关要求 ...

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration [2] Group 1 - The approval of the drug registration certificate marks a significant milestone for the company in expanding its product portfolio [2] - Mosapride Citrate is expected to enhance the company's competitive position in the pharmaceutical market [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-097 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于全资子公司获得枸橼酸莫沙必利片 二、药品的其他相关情况 1 3、规格： 5mg（按 C21H25ClFN3O3·C6H8O7计） 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、受理号：CYHS2400126 7、药品批准文号：国药准字 H20255193 8、药品批准文号有效期：至 2030 年 08 月 25 日 9、上市许可持有人：宁波美诺华天康药业有限公司 10、生产企业：宁波美诺华天康药业有限公司 药品适应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎） 引起的消化道症状，包括烧心、嗳气、恶心、呕吐、早饱、上腹胀、上腹痛等。 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有 ...

Core Viewpoint - Meinuohua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product [1] Group 1 - The drug is indicated for improving gastrointestinal symptoms caused by decreased gastrointestinal motility, such as functional dyspepsia and chronic gastritis [1] - Symptoms addressed by the drug include heartburn, belching, nausea, vomiting, early satiety, upper abdominal bloating, and upper abdominal pain [1]

Core Viewpoint - Meihua's subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Mosapride Citrate Tablets, which are indicated for improving gastrointestinal symptoms caused by reduced gastrointestinal motility [1] Group 1 - The approved drug is intended for symptoms such as heartburn, belching, nausea, vomiting, early satiety, upper abdominal distension, and upper abdominal pain [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company has shown significant growth in its main business, with a notable increase in revenue and net profit in the first half of 2025, indicating a turning point in its operations [5] - The company is expected to achieve substantial revenue growth in the coming years, driven by its innovative business layout and expansion in various segments [5] Summary by Relevant Sections Financial Performance - In the first half of 2025, the company achieved revenue of 677 million yuan, a year-on-year increase of 11.42%, and a net profit attributable to shareholders of 49 million yuan, up 158.97% [5] - The second quarter of 2025 saw revenue of 401 million yuan, a year-on-year growth of 16.15%, and a net profit of 28 million yuan, reflecting a significant increase of 468.03% [5] - The gross margin for the first half of 2025 was 32.45%, an increase of 2.94 percentage points, while the net margin was 7.84%, up 4.34 percentage points [5] Business Segments - The formulation segment reported revenue of 262 million yuan in the first half of 2025, a year-on-year increase of 111.03%, driven by the successful commercialization of its projects [5] - The active pharmaceutical ingredient (API) business is stabilizing, with new product registrations ongoing, and the company has established solid supply relationships with major pharmaceutical firms [5] - The CDMO (Contract Development and Manufacturing Organization) segment is expanding, with ongoing collaborations with major clients and new project developments [5] Future Outlook - Revenue projections for 2025-2027 are 1.603 billion, 1.982 billion, and 2.389 billion yuan, with year-on-year growth rates of 16.77%, 23.69%, and 20.49% respectively [5] - The net profit attributable to shareholders is expected to reach 129 million, 164 million, and 208 million yuan for the same period, with growth rates of 92.98%, 27.16%, and 27.04% respectively [5] - The company's stock is currently trading at a price-to-earnings ratio (P/E) of 23, 18, and 14 for the years 2025, 2026, and 2027, respectively, indicating a favorable valuation given the expected growth [5]

Meeting Information - The first temporary shareholders' meeting of Ningbo Meinuo Pharmaceutical Co., Ltd. will be held on September 11, 2025, at 14:00 in Ningbo, Zhejiang Province [1] - The voting method will combine on-site and online voting, with specific time slots for each [1] Meeting Agenda - The agenda includes a proposal to abolish the supervisory board and amend the company's articles of association [4][5] - The proposal has been approved by the company's board of directors and supervisory board [5] Voting Procedures - Shareholders must sign in 10 minutes before the meeting and present necessary identification [2] - Voting will be conducted through a named voting method, and any blank votes will be considered abstentions [3] Legal Compliance - The meeting will be conducted in accordance with the Company Law of the People's Republic of China, the Securities Law, and the company's articles of association [2][4] - A lawyer will be present to provide legal opinions on the meeting's compliance with relevant laws [4][5] Proposal Details - The proposal to abolish the supervisory board will transfer its responsibilities to the audit committee of the board of directors [4] - Amendments to the articles of association will reflect this change and have been prepared in a draft for review [5] Shareholder Rights - Shareholders have the right to participate in discussions related to the agenda and vote accordingly [2][3] - The company will ensure that the meeting is conducted in a serious and orderly manner, allowing only authorized personnel to attend [2]

宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 中国·宁波 二○二五年九月十一日 1 | | | 宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 会 议 议 程 一、会议时间、地点 召开时间：2025 年 9 月 11 日，14：00 召开地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室 二、会议议程 1、会议主持人宣布大会开始，推选计票人、监票人各两名； 2、董事会秘书宣读大会会议须知； 3、会议主持人介绍会议议案： | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于撤销监事会并修订《公司章程》的议案 | | 2.00 | 关于修订、制定公司部分管理制度的议案 | | 2.01 | 股东会议事规则 | | 2.02 | 董事会议事规则 | | 2.03 | 独立董事工作制度 | | 2.04 | 对外投资管理制度 | | 2.05 | 对外担保管理制度 | | 2.06 | 关联交易管理制度 | | 2.07 | ...